Navigation Links
Raloxifene Cuts Risk of Certain Type of Breast Cancer
Date:6/11/2008

And the benefits weren't limited to high-risk women, study finds

WEDNESDAY, June 11 (HealthDay News) -- A drug already approved to reduce the risk of breast cancer in high-risk women also seems to cut the risk for other women.

A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.

Raloxifene did not, however, cut the risk for noninvasive breast cancer or invasive ER-negative cancers.

"This is a reaffirmation that the drug raloxifene is a very powerful SERM [selective estrogen receptor modulator] for reducing the risk of invasive breast cancer," said Dr. Jay Brooks, chief of hematology/oncology at Ochsner Health System in Baton Rouge, La.

The study, published in the June 10 online issue of the Journal of the National Cancer Institute, was funded by Eli Lilly and Co., which makes Evista.

SERMs block the female hormone estrogen by binding to estrogen receptors; estrogen helps fuel the growth of some breast cancers. Raloxifene and other hormonal therapies have an "estrogenic tickle" effect, explained V. Craig Jordan, author of an accompanying editorial in the journal and vice president and research director for medical science at Fox Chase Cancer Center in Philadelphia. Jordan did some of the early laboratory research on raloxifene.

Raloxifene was originally developed to prevent and treat osteoporosis, and only later was found to help reduce the risk of invasive breast cancer in high-risk women.

The new study expands on the original results of the RUTH (Raloxifene Use for the Heart) trial, originally designed to see if raloxifene, which has cholesterol-lowering properties, could reduce the risk of dying from coronary heart disease.

The trial involved more than 10,000 postmenopausal women with
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Raloxifene Safe for Women With Decreased Kidney Function
2. Consumers Urged to Avoid Certain Tomatoes Amid Salmonella Scare
3. Demonstrating the Value of Benchmarking in an Uncertain Economy
4. St. Jude finds young age may give survival advantage to children with certain brain tumors
5. Certain Tests in ERs Raise Cancer Risk for Some
6. Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
7. Gypsum Wallboard from CertainTeeds Moundsville, W. Va., Plant and Roofing Shingles among Building Materials Donated to St. Jude Dream Home(R)
8. Regular prostate-specific antigen screening may be discontinued in certain elderly populations
9. Experimental drug shows promise in treating certain lymphomas
10. Study finds certain liver disease related to cardiovascular fitness
11. Womens Risk for a Certain Skin Cancer Varies by Geography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... highlights, Brian Williams refreshing old school rap classics, and ... A University of Colorado Cancer Center study published in ... also allows researchers, journals, and health advocates to connect ... and prevention. , "No matter what field you,re in, ... around the world," says Chante Karimkhani, MD candidate in ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... study published in the scientific journal Nature Neuroscience ... researchers at Universit Laval, reveals that it is possible ... involves rekindling pain so that it can subsequently be ... alleviate chronic pain. , The researchers from the Faculty ... sant mentale de Qubec (IUSMQ) were inspired by previous ...
(Date:7/8/2014)... in Memory Restoration has been awarded up to $15 ... for a four -year project aiming to help brain-injured ... experts in neurosurgery, engineering, neurobiology, psychology and physics will ... prosthesis in the brain. , Memory is the process ... encode information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... Will Set Key Industry Records, CARROLLTON, Texas, Sept. ... of medical imaging facilities, has,announced it has begun construction ... project, in Sherman, Texas, represents several,firsts of its kind. ... Texas, it is the first,joint venture between multiple hospitals ...
... and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker of ... Massachusetts has,granted final approval of a $52.5 million ... against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... provides evidence that noncoding RNAs and interactions between noncoding ... than was previously understood. The research, published by Cell ... Cell, may be useful for identifying tumor-specific signatures associated ... cells exhibit genetic alterations in oncogenes or tumor suppressor ...
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... ... Conference, Majority of Students Polled Think Health Centers Need to Improve their ... ... 2007 Sexual Health Report Card, the second,annual ranking of sexual health resources at American colleges ...
... CITY, Calif., Sept. 10 Genomic,Health, Inc. (Nasdaq: ... studies that,support the use of quantitative real-time polymerase ... assay, for measuring the hormone,receptors, estrogen receptor (ER) ... A separate study identified multiple genes,including the 21 ...
Cached Medicine News:Health News:Fry Construction Selected for High-Profile Medical Imaging Project 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas 2Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 2Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 3Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 4Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 5Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 6Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 7Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 8Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 9Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 10Health News:Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card 11Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 2Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 3Health News:Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium 4
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... March 20 Valor Medical, an emerging medical,device company ... human,implant of Neucrylate AN for treatment of cerebral aneurysms ... Tehran. The treatment was under the,guidance of a clinical ... Committee., Dr. Pakbaz stated that the patient,s aneurysm ...
... for more ... anticoagulation patients, INDIANAPOLIS, March ... meter training, equipment and supplies for all long-term,warfarin users who ... The change opens the door to greater convenience and,potentially fewer ...
Cached Medicine Technology:Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 2Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 3Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: